AbbVie: Dominating Immunology While Building Oncology Upside
Source: SeekingAlpha
2026-02-17 01:11:27 ET
AbbVie ( ABBV ), a leader in the JAK and IL-23 inhibitor markets, released strong Q4 numbers, but its stock price fell 5.1% that day. And first, I will note the dry numbers....
Read the full article on Seeking Alpha
For further details see:
AbbVie: Dominating Immunology While Building Oncology Upside
AbbVie Inc.
NASDAQ: ABBV
ABBV Trading
-0.97% G/L:
$224.48 Last:
1,406,476 Volume:
$226.89 Open:
ABBV Latest News
March 13, 2026 01:36:56 pm
Concorde Financial Exits Howard Hughes Holdings, Developer of Large Sun Belt Communities
ABBV Stock Data
$396,361,630,803
1,749,710,786
N/A
2503
N/A
Pharmaceuticals
Healthcare
US
North Chicago
